Encavis AG
XMUN:ECV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Encavis AG
XMUN:ECV
|
DE |
|
C
|
Careium AB (publ)
F:I81
|
SE |
|
A
|
Astellas Pharma Inc
XMUN:YPH
|
JP |
|
Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
|
US |
|
B
|
Beijing Enterprises Holdings Ltd
F:BJEB
|
HK |
|
H
|
Hellenic Telecommunications Organization SA
XMUN:OTE
|
GR |
|
E
|
European Metals Holdings Ltd
F:E86
|
AU |
|
C
|
China Evergrande Group
XMUN:EV1
|
CN |
|
W
|
WashTec AG
XMUN:WSU
|
DE |
|
B
|
Beijing Enterprises Holdings Ltd
XMUN:BJEB
|
HK |
|
D
|
Daphne International Holdings Ltd
XMUN:PSX
|
CN |
|
B
|
B&G Foods Inc
XMUN:DHR
|
US |
|
F
|
Forbes Energy Services Ltd
OTC:FLSS
|
US |
|
Airspan Networks Holdings Inc
OTC:MIMOQ
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ECV's stock price target?
Not Available
ECV does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Encavis AG?
Projected CAGR
6%
Over the last 7 years, the compound annual growth rate for Revenue has been 19%. The projected CAGR for the next 4 years is 6%.
What is the Operating Income forecast for Encavis AG?
Projected CAGR
8%
Over the last 7 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 3 years is 8%.